Boehringer Ingelheim Receives Approval for its Classical Swine Fever Live Vaccine in China

Shots:

• Boehringer’s Ingelvac CSF MLV has obtained a New Veterinary Drug Registration Certificate from the Ministry of Agriculture and Rural Affairs of China
• The vaccine is jointly developed by Boehringer and Chinese research institutes and will be produced at BI’s Taizhou plant, Jiangsu province, and is expected to be commercialized in H1’21
• The vaccine is the BI’s first swine vaccine product, developed, manufactured and distributed in China. The plant also manufactures Ingelvac PRRS MLV (live vaccine for porcine reproductive and respiratory syndrome)

Click here ­to­ read full press release/ article | Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim